This guidance represents the view of NICE, arrived at after careful consideration of the evidence available. When exercising their judgement, healthcare professionals are expected to take this guidance fully into account, and specifically any special arrangements relating to the introduction of new inter...
This guideline covers assessment and early management of head injury in babies, children, young people and adults. It aims to ensure that people have the right care for the severity of their head injury, including direct referral to specialist care if needed....
Evidence-based recommendations on risankizumab (Skyrizi) for previously treated moderately to severely active Crohn's disease in people 16 years and over....
NICE is unable to make a recommendation on ciltacabtagene autoleucel (Carvykti) for treating relapsed or refractory multiple myeloma in adults. This is because Janssen withdrew its evidence submission for the appraisal. We will review this decision if the company decides to make a submission....
Evidence-based recommendations on difelikefalin (Kapruvia) for pruritus in adults with chronic kidney disease having haemodialysis....
Six digitally enabled therapies can be used as treatment options for
adults with anxiety disorders while further evidence is generated on their
clinical and cost effectiveness, once they have appropriate approval.
The following technologies can only be used once they have Digital
Technology Assessment Cr...
Three digitally enabled therapies can be used as treatment options for
adults with depression while further evidence is generated on their
clinical and cost effectiveness. The therapies should be used with
support from a trained practitioner or therapist in NHS Talking Therapies
for anxiety and depressio...
People with BRCA mutation-positive HER2‑negative high-risk early breast cancer usually have chemotherapy followed by surgery (neoadjuvant chemotherapy), or surgery followed by chemotherapy (adjuvant chemotherapy).
Clinical trial evidence shows that, compared with placebo, olaparib after neoadjuvant or...
This evaluation uses new cost-effectiveness estimates to update olaparib for previously treated BRCA mutation-positive hormone-relapsed metastatic prostate cancer (NICE technology appraisal guidance TA831). No new clinical evidence was reviewed. Treatments for BRCA mutation-positive hormone-relapsed meta...
Evidence-based recommendations on olaparib (Lynparza) for previously treated BRCA mutation-positive hormone-relapsed metastatic prostate cancer in adults.
Commercial arrangement
There is a simple discount patient access scheme for olaparib. NHS organisations can get details on the Commercial Access and ...
